Stevenage, United Kingdom
Stevenage, United Kingdom

Time filter

Source Type

Patent
Glaxo Group Ltd | Date: 2015-06-02

A package which can be torn open by a user, comprising a polymer film material having a preferential tearing direction and defining a cavity for a product, wherein the polymer film material incorporates a bias facilitating tearing along a tear line oriented in a direction other than its preferential tearing direction and a tear initiation location which facilitates tearing of the polymer film material in its preferential tearing direction to open the package, the tear line being adjacent to a tear initiation location. The polymer film material having a preferential tearing direction provides resistance against a child tearing open the package.


Patent
Glaxo Group Ltd | Date: 2016-10-14

The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD), diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularisation, and polynucleotide sequences encoding said antigen binding constructs.


Patent
Glaxo Group Ltd | Date: 2016-10-14

The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.


Patent
Glaxo Group Ltd | Date: 2016-12-01

The present invention is directed to novel retinoid-related orphan receptor gamma (ROR) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR.


Patent
Glaxo Group Ltd | Date: 2017-01-04

Muscarinic Acetylcholine Receptor Antagonists and therapeutic methods of using them are provided.


Patent
Glaxo Group Ltd | Date: 2016-02-05

Metering valves for use in a metered dose inhaler that include a valve body, a first stem seal including a first elastomeric material, a second stem seal including a second elastomeric material different from the first elastomeric material, and a valve stem slidably engaged with at least one of the first stem seal and the second stem seal as well as sealed containers configured to contain an aerosol pharmaceutical formulation that include a container having an opening therein, a cap covering the opening in the container, a metering valve adjacent the cap, and a cap seal positioned between the cap and the container to provide a sealed container where the metering valve include at least one stem seal that includes a first elastomeric material, and the cap seal includes a second elastomeric material different from the first elastomeric material are described.


Patent
Glaxo Group Ltd | Date: 2016-06-24

A new pharmaceutical formulation for retinoid-containing soft gelatin capsules is disclosed. The new formulation comprises a soft gelatin capsule filled with a fill mass comprising a retinoid as an active ingredient, a natural vegetable oil, a partially hydrogenated natural vegetable oil and medium chain triglycerides. Optionally, the new formulation also comprises a natural wax. In a particularly preferred embodiment, the soft gelatin capsule comprises pig gelatin in the capsule shell in combination with the above fill mass.


Patent
Glaxo Group Ltd | Date: 2016-09-01

A novel crystalline form of a compound is disclosed.


Patent
Glaxo Group Ltd | Date: 2016-08-19

A compound of formula (I):


Patent
GLAXO GROUP Ltd | Date: 2016-02-25

An assembly having: a container configured to contain a product, the container having an end having a dispensing end surface, a central axis which extends through the end, and a neck underneath the end, the neck having an outer surface which tapers outwardly away from the central axis as it extends in a direction towards the end; an accessory non-removably mounted on the end of the container, the accessory having a surface bearing against the dispensing end surface of the container, and a sleeve disposed about the neck so that an inner surface of the sleeve is in facing relation with the neck outer surface, and; an annular collar wedged between the sleeve inner surface and the neck outer surface and joined to the sleeve inner surface by a permanent joint.

Loading Glaxo Group Ltd collaborators
Loading Glaxo Group Ltd collaborators